Sign In
Buy SNDX
$19.05
-0.430 (-2.21%)
At Close: Jul 31, 2026
Wall Street Analysts Predict a 45% Upside in Syndax (SNDX): Here's What You Should Know
02:55pm, Monday, 19'th Dec 2022 Zacks Investment Research
The consensus price target hints at a 44.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Syndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain Prospect
03:11am, Saturday, 10'th Dec 2022
How informed are you about binding interactions of Menin with the mixed lineage leukemia 1 protein for the treatment of acute myeloid leukemia? Neither am I. This analysis has been supported by the In
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
09:47am, Tuesday, 06'th Dec 2022
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
What Makes Syndax (SNDX) a Good Fit for 'Trend Investing'
10:32am, Friday, 02'nd Dec 2022
Syndax (SNDX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Call Transcript
11:52am, Sunday, 06'th Nov 2022
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive
Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
07:00am, Thursday, 27'th Oct 2022
WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today anno
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call Transcript
07:55pm, Monday, 08'th Aug 2022
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive O
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
04:34pm, Monday, 08'th Aug 2022
Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
12:50pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
10:32am, Thursday, 04'th Aug 2022
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "
Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?
01:55pm, Monday, 01'st Aug 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?
11:37am, Monday, 01'st Aug 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Syndax Announces Participation at Two Upcoming Investor Conferences
07:00am, Thursday, 26'th May 2022
WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipelin
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
10:25pm, Monday, 09'th May 2022 Zacks Investment Research
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022
02:07pm, Monday, 11'th Apr 2022 Benzinga
Upgrades
Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $0.41 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the st
